Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges?

Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges?

published under permission of Elsevier Treatment of chronic hepatitis C has significantly improved over the last two decades as depending on the HCV genotype 40-90% of patients achieve a sustained virological response (SVR). However, treatment with (pegylated-) interferon alfa (PEG-IFN) and ribavirin (RBV) is still associated with frequent and sometimes severe side effects and many patients can...

New Hopes and Challenges for Treatment of Neurodegenerative Disorders: Great Opportunities for Young Neuroscientists

New treatment of hepatitis C (Direct Acting Antiviral)

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy an...

Treatment for advanced melanoma: new drugs, new opportunities, new challenges.

The standard of care for the treatment of patients with metastatic melanoma has changed fundamentally based on two new treatment strategies that are, conceptually and biologically, largely independent: the blockade of immune regulatory molecules with monoclonal antibodies (termed “immune checkpoint blockade”) and the inhibition of BRAF V600 mutation–driven mitogen-activated protein kinase (MAPK...

[New paradigm for treatment of chronic hepatitis C virus infection].

교신저자: 정우진, 700-712, 대구시 중구 달성로 56, 계명대학교 의과대학 내과학교실 Correspondence to: Woo Jin Chung, Department of Internal Medicine, School of Medicine Keimyung University, 56 Dalsung-ro, Jung-gu, Daegu 700-712, Korea. Tel: +82-53-250-7088, Fax: +82-53-250-7442, E-mail: [email protected] Financial support: None. Conflict of interest: None. 요약: 페그인터페론의 등장 이후로 만성 C형간염의 치료 성적은 유의하게 개선되어 왔지만 치료시 동반되는 부작용과 일부 유전...